PPTA Statements

PPTA Recognizes World PI Week: April 22-29, 2016

April 22, 2016—The Plasma Protein Therapeutics Association (PPTA) stands together with the global primary immunodeficiency community to promote World PI Week, a global campaign aimed to raise awareness and improve diagnosis and treatment of PI.

Continue reading

  • Created on .

PPTA Statement on MSM Donor Policy

[Blood Products Advisory Committee Meeting on December 2, 2014]

The Plasma Protein Therapeutics Association (PPTA) is the international trade association and standards-setting organization for the world’s major producers of plasma-derived and recombinant analog therapies, collectively referred to as plasma protein therapies. Plasma protein therapies are used in the treatment of a number of rare diseases.

Continue reading

  • Created on .

Ebola Virus and Plasma Protein Therapies

During the October, 21 2016, Source Board of Directors meeting, the Board agreed to remove the voluntary deferral for 60 days of donors returning from Ebola virus disease affected areas in the previous 60 days. The deferral was originally implemented on or about October 13, 2014.

Continue reading

  • Created on .

PPTA Letter to Stakeholders re: European Data Program Update

Dear PPTA Stakeholders:

I would like to provide a status report on implementation of PPTA’s European Data Program.

As you know, PPTA launched the program in November 2013 starting with the reporting of Recombinant Factor VIII data. We committed as well to soon begin reporting data on a more complete set of plasma protein therapies. Today we are able to honor that commitment. Please click here to access the data.

Continue reading

  • Created on .

PPTA's Updated Response to Ontario's Proposal to Ban Compensated Plasma Donation

The Plasma Protein Therapeutics Association (PPTA) remains deeply concerned about the proposal to ban compensated plasma donation in the Province of Ontario, Canada. The proposed legislation, Ontario Bill 178, unfairly targets compensated plasma donation on alleged bases of safety and Canada’s goal of self-sufficiency in regards to the supply of plasma-derived medicinal products.

Continue reading

  • Created on .

PPTA Statement on Signing of Health Care Reform Bill

The Plasma Protein Therapeutics Association released the following statement regarding passage of the H.R. 3590, the Patient Protection and Affordable Care Act:

"PPTA recognizes the historic achievement of President Obama and Congress in providing affordable, quality health care to millions of Americans.

Continue reading

  • Created on .
Copyright © 2018 PPTA. All rights reserved. (202) 789-3100